Return to Listing

5 result(s) for Lung Cancers

PI Name Protocol # Title
Eric Anderson IRB00010866 Safety and Efficacy of nab®-paclitaxel (Abraxane®) in Combination with Carboplatin as First Line Treatment in Elderly Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study
Jeremy Cetnar IRB00011046 S1400, Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Khaled Tolba IRB00011462 A Randomized, Open-Label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib (AZD6244) plus nab-Paclitaxel as Second-Line Treatment for Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
Matthew Taylor IRB00011804 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Khaled Tolba IRB00011967 An open label, multicenter, phase 2 study to determine the safety and efficacy of BIND-014 (docetaxel nanoparticles for injectable suspension) as a second-line therapy for patients with KRAS mutation positive or Squamous cell non-small cell lung cancer

You may also qualify for Phase 1 Program trials.

For more information:
Call: 503-494-1080